Under the agreement, Cyclotek will produce and provide doses of Tb-labeled RAD 402 to support Radiopharm's upcoming Phase 1 clinical trial in prostate cancer in Australia. The Phase 1 trial is anticipated to start in the second half of 2025. RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025 SYDNEY and BUNDOORA, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Radiopharm T ...

RAD101 in U.S. Phase 2 clinical trial to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin SYDNEY, June 11, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track De ...

As the June 18 deadline for bidding on the remaining assets of Rite Aid nears, the potential buyers who are looking them over reportedly include pharmacy chain Walgreens, reality star turned entrepreneur Kourtney Kardashian, consumer-focused private equity firms, and three brand management companies: Authentic Brands Group, WHP Global and Marquee Brands.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, i ...

Phase 1 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors Previous clinical proof-of concept data for targeting HER-2 demonstrated the safety and biodistribution of 99mTc-RAD202 in humans SYDNEY, June 04, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncol ...

Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers Data completes preclinical package for Investigational New Drug submission in mid-2025 with Phase 1 therapeutic study initiation expected in 4Q25 SYDNEY, Australia, June 02, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of hig ...

公司业绩与财务表现 - 2025年第一季度营收达2.03亿美元，超出预期的2.0221亿美元，同比增长3% [1] - 调整后EBITDA增至6980万美元，利润率从31.7%提升至34.4% [1] - 净利润1110万美元，扭转上年同期100万美元亏损 [1] - 制药制造商解决方案部门收入增长17%，订阅收入因Kroger Savings Club逐步退出下降7% [2] - 重申2025全年营收指引8.1-8.4亿美元，上调调整后EBITDA预期至2.73-2.87亿美元（2024年为2.602亿美元） [3] 分析师预测调整 - 2025年营收预期微调至8.17亿美元（同比增长3%），主因Rite Aid带来约500万美元逆风，但被制药制造商解决方案部门强劲表现和利润率改善抵消 [4] - 调整后EBITDA预期上调至2.79亿美元（增长7%），利润率扩大135个基点至34.2% [4] - 尽管2025年下半年销售与营销费用可能小幅增加，但利润率优势预计持续 [4] 行业趋势与公司前景 - 药房成本向消费者转移的趋势及药店/PBMs争夺废弃处方的努力，有利于公司价值主张 [5] - 预计2025年及以后将实现稳健增长、执行力和利润率扩张，受益于ISP采用率和医疗保健消费者意识提升 [5] - 摩根大通维持7美元目标价，基于9倍2026年EBITDA倍数（预测2.98亿美元）及中高个位数EBITDA持续增长轨迹 [6] 股价表现 - 当前股价下跌0.88%至3.93美元 [6]

Rite Aid is reportedly closing additional stores while handing off business to rivals.The drugstore chain, which recently filed for bankruptcy for the second time, has revealed 95 locations it wants to shut down, Fast Company reported, citing a court filing.The locations are spread across six states, but are primarily based in Rite Aid’s home state of Pennsylvania, where the company plans to close more than 70 stores. In total, Rite Aid has targeted 210 stores for closure, the report said.The filing came on ...

CVS Health confirmed interest in so-called “prescription files” of Rite Aid customers from the ... More bankrupt chain’s stores in the Pacific Northwestern U.S. The bid by CVS comes after Rite Aid earlier this month said it is “pursuing a strategic and value-maximizing sale process for substantially all of its assets,” the company said on May 5, 2025. “To facilitate this process, the company and its subsidiaries commenced voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of New ...

For more information: Investors: Riccardo Canevari CEO & Managing Director P: +1 862 309 0293 E: rc@radiopharmtheranostics.com Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning pepti ...

Rite Aid has claimed in a court filing Tuesday (May 6) that its inability to sustain a successful recovery and its subsequent return to bankruptcy protection is primarily due to sparsely stocked store shelves and to trade-down from lower-income consumers.In this court declaration, Marc Liebman, Rite Aid’s chief transformation officer, detailed how post-emergence inventory shortages created a “vicious cycle” where diminishing liquidity led to empty shelves, and vice versa.The core of the inventory issue stem ...